Vivo Capital

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Cerebral Therapeutics, Inc. is a pharmaceutical company that develops implanted drug-device combination therapies for the treatment of neurologic diseases. The company uses implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose for the formulation of anti-epileptic drug valproic acid, called CT-010, to treat refractory epilepsy. Cerebral Therapeutics, Inc. was formerly known as Cerebral Therapeutics LLC. The company was incorporated in 2010 and is based in Aurora, Colorado.

Arrowhead and Vivo formed Visirna Therapeutics as a joint venture to bring four of the biotech's RNAi therapies to China. Through a licensing agreement, the company will focus on four of Arrowhead's therapies for cardiometabolic diseases.

Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Ablaze Pharma is a clinical stage bio-pharmaceutical company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Aadi Bioscience, Inc. is a clinical stage biopharmaceutical company based in Pacific Palisades, California, founded by Dr. Neil Desai in 2011. The company focuses on the development of a potentially best-in-class mTOR inhibitor, specifically ABI-009, aimed at treating patients with oncology, cardiovascular, and metabolic diseases. Aadi Bioscience is dedicated to addressing unmet medical needs through its innovative therapeutic approaches in these areas.

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

Esco Lifesciences Group specializes in providing technology-based products and services aimed at the life sciences and healthcare sectors. The company supports various aspects of academic research, scientific discoveries, clinical practice, and biopharmaceutical research and development. Its offerings are designed to facilitate the invention, discovery, and commercialization processes in the industry, ultimately enabling customers to lead healthier and safer lives through advanced technological solutions.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, with a focus on developing innovative antibody-drug conjugate therapies for late-stage multiple myeloma and prostate cancer. The company was established based on technology exclusively licensed from the University of California, San Francisco, and developed in the laboratory of Dr. Bin Liu. Fortis Therapeutics aims to enhance treatment options for patients suffering from advanced adenocarcinoma and neuroendocrine cancer, leveraging its proprietary platform to create targeted therapies that improve clinical outcomes in late-stage cancer treatment.

Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraines. The company's primary product candidate, STS101, is a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine mesylate. This medication is designed for self-administration using a pre-filled, single-use nasal delivery device. Currently, STS101 is undergoing Phase III clinical trials, marking a significant step in its development process. Founded in 2016 and based in South San Francisco, California, Satsuma Pharmaceuticals aims to provide effective solutions for individuals suffering from acute migraine attacks.

ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.

InnoCare Pharma Limited is a biopharmaceutical company focused on developing innovative treatments for cancer and autoimmune diseases. Founded in 2015 and headquartered in Wanchai, Hong Kong, InnoCare operates additional offices in major cities across China and in Cambridge, Massachusetts. The company is advancing several clinical programs, including Orelabrutinib, which targets various B-cell malignancies and is currently undergoing registrational trials. It is also developing ICP-192, a pan-inhibitor of fibroblast growth factor receptor, and ICP-105, which targets FGFR4 in advanced hepatocellular carcinoma. InnoCare's preclinical pipeline includes promising candidates aimed at treating specific cancer types and autoimmune disorders. The firm is supported by a highly qualified scientific team and a specialized advisory board, reinforcing its commitment to pushing the boundaries of drug innovation and improving patient outcomes.

Design Therapeutics, Inc. is a clinical-stage biotechnology company based in Solana Beach, California, focused on developing innovative therapies for degenerative disorders resulting from nucleotide repeat expansions. Founded in 2017, the company is advancing its lead program aimed at treating Friedreich's ataxia, while also exploring treatment options for other conditions such as Fragile X syndrome and myotonic dystrophy. Design Therapeutics is known for its GeneTACTM molecules, a new class of small-molecule gene-targeted therapies designed to address the underlying causes of diseases linked to inherited nucleotide repeat expansion mutations. The company's ongoing research efforts seek to develop disease-modifying treatments for serious conditions driven by these genetic factors.

Serán is a contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies.

Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

Serán is a contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral, small-molecule drugs for the treatment of cancer and liver diseases, particularly non-alcoholic steatohepatitis (NASH). Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company leverages its expertise in disease biology and medicinal chemistry to advance a pipeline of innovative therapeutic candidates. Key products include TERN-101, a non-bile acid farnesoid X receptor agonist, and TERN-201, an inhibitor of semicarbazide-sensitive amine oxidase. Terns Pharmaceuticals aims to address significant unmet medical needs both in China and globally through its efficient drug discovery model and extensive clinical development capabilities.

Provivi Inc. develops biopesticides for agriculture, commercial, household, and public health pest management. It develops research quantities of carbene/nitrene transferase enzymes that activate diazo and azide compounds to generate iron-carbenoids and iron-nitrenoids through a mode of activation. The company also develops a biocatalysis and fermentation technology, which is based on biocatalysts that enable efficient synthesis of biopesticides. Its technology has applications in industries, such as pharmaceuticals, nutrition, flavors, and fragrances. The company offers its products through distributors worldwide. Provivi Inc. was incorporated in 2012 and is based in Santa Monica, California.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.

ESSA Pharma Inc. is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada, established in 2009. The company specializes in developing novel therapies for the treatment of advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (CRPC). ESSA is advancing its lead product candidate, EPI-7386, which is an oral small molecule designed to selectively block the amino-terminal domain of the androgen receptor (AR). This mechanism targets a critical component necessary for the growth and survival of prostate cancer cells, aiming to address the resistance mechanisms associated with current therapies. By focusing on this specific target, ESSA seeks to enhance the treatment options and improve survival outcomes for patients suffering from CRPC.

Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.

Citrine Medicine is a rare disease-focused pharmaceutical firm.

Tranquis Therapeutics, Inc., a biotechnology company, engages in developing immuno-therapeutics for neurodegenerative and aging-related diseases. Its TQS-168 is a therapeutic candidate that targets underlying myeloid immune cell dysfunction that is linked to a variety of nervous system disorders. Its solution is used to treat amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and age-related cognitive impairment. The company was incorporated in 2016 and is based in San Mateo, California.

Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies. Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&L constraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines. Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation. Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON. Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications.

Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, specializing in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions and other diseases with high unmet needs. The company's lead product candidate, TP-03, is currently undergoing Phase IIb/III trials for the treatment of blepharitis caused by Demodex mite infestations, as well as meibomian gland disease. In addition to TP-03, Tarsus is advancing other candidates such as TP-04 for the treatment of rosacea and TP-05 aimed at Lyme disease prophylaxis and malaria reduction. With a focus on addressing significant market opportunities, Tarsus Pharmaceuticals is committed to providing first-in-class therapies where treatment options are currently limited.

Cerebral Therapeutics, Inc. is a pharmaceutical company that develops implanted drug-device combination therapies for the treatment of neurologic diseases. The company uses implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose for the formulation of anti-epileptic drug valproic acid, called CT-010, to treat refractory epilepsy. Cerebral Therapeutics, Inc. was formerly known as Cerebral Therapeutics LLC. The company was incorporated in 2010 and is based in Aurora, Colorado.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Cerebral Therapeutics, Inc. is a pharmaceutical company that develops implanted drug-device combination therapies for the treatment of neurologic diseases. The company uses implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose for the formulation of anti-epileptic drug valproic acid, called CT-010, to treat refractory epilepsy. Cerebral Therapeutics, Inc. was formerly known as Cerebral Therapeutics LLC. The company was incorporated in 2010 and is based in Aurora, Colorado.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

InnoCare Pharma Limited is a biopharmaceutical company focused on developing innovative treatments for cancer and autoimmune diseases. Founded in 2015 and headquartered in Wanchai, Hong Kong, InnoCare operates additional offices in major cities across China and in Cambridge, Massachusetts. The company is advancing several clinical programs, including Orelabrutinib, which targets various B-cell malignancies and is currently undergoing registrational trials. It is also developing ICP-192, a pan-inhibitor of fibroblast growth factor receptor, and ICP-105, which targets FGFR4 in advanced hepatocellular carcinoma. InnoCare's preclinical pipeline includes promising candidates aimed at treating specific cancer types and autoimmune disorders. The firm is supported by a highly qualified scientific team and a specialized advisory board, reinforcing its commitment to pushing the boundaries of drug innovation and improving patient outcomes.

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.

Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral, small-molecule drugs for the treatment of cancer and liver diseases, particularly non-alcoholic steatohepatitis (NASH). Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company leverages its expertise in disease biology and medicinal chemistry to advance a pipeline of innovative therapeutic candidates. Key products include TERN-101, a non-bile acid farnesoid X receptor agonist, and TERN-201, an inhibitor of semicarbazide-sensitive amine oxidase. Terns Pharmaceuticals aims to address significant unmet medical needs both in China and globally through its efficient drug discovery model and extensive clinical development capabilities.

TOT Biopharm Company Limited is a clinical-stage biopharmaceutical firm based in Suzhou, China, focused on the development, manufacture, and marketing of innovative oncology drugs and therapies. Founded in 2010, the company specializes in therapeutic biological products, particularly anti-tumor drugs and specialty medicines. One of its notable products is S-1, an oral medication that combines tegafur, gimeracil, and oteracil potassium, designed to enhance the delivery and efficacy of 5-fluorouracil, a key chemotherapeutic agent. TOT Biopharm is committed to establishing a trusted brand in oncology treatments, with a diverse pipeline that includes monoclonal antibodies and antibody-drug conjugates aimed at improving patient outcomes in cancer care. The company's operations primarily generate revenue in Mainland China.

Sinovac Biotech Ltd. is a biopharmaceutical company based in Beijing, China, specializing in the research, development, manufacture, and commercialization of vaccines for human infectious diseases. Its product portfolio includes vaccines for hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza, mumps, and enterovirus 71, among others. Key marketed products include Healive, a hepatitis A vaccine, Bilive, a combined hepatitis A and B vaccine, and Panflu.1, which was the first H1N1 vaccine approved globally. Sinovac also plays a significant role in government stockpiling programs for vaccines in China. The company is actively developing new vaccines, including those for pneumococcal disease and rubella, with various clinical trials underway. Sinovac collaborates with notable institutions such as GlaxoSmithKline and Tianjin CanSino Biotechnology to enhance its vaccine development efforts. Established in 1999, Sinovac primarily sells its products in China while also exporting selected vaccines to countries like Mongolia, Nepal, and the Philippines.

Cerebral Therapeutics, Inc. is a pharmaceutical company that develops implanted drug-device combination therapies for the treatment of neurologic diseases. The company uses implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose for the formulation of anti-epileptic drug valproic acid, called CT-010, to treat refractory epilepsy. Cerebral Therapeutics, Inc. was formerly known as Cerebral Therapeutics LLC. The company was incorporated in 2010 and is based in Aurora, Colorado.

Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

InnoCare Pharma Limited is a biopharmaceutical company focused on developing innovative treatments for cancer and autoimmune diseases. Founded in 2015 and headquartered in Wanchai, Hong Kong, InnoCare operates additional offices in major cities across China and in Cambridge, Massachusetts. The company is advancing several clinical programs, including Orelabrutinib, which targets various B-cell malignancies and is currently undergoing registrational trials. It is also developing ICP-192, a pan-inhibitor of fibroblast growth factor receptor, and ICP-105, which targets FGFR4 in advanced hepatocellular carcinoma. InnoCare's preclinical pipeline includes promising candidates aimed at treating specific cancer types and autoimmune disorders. The firm is supported by a highly qualified scientific team and a specialized advisory board, reinforcing its commitment to pushing the boundaries of drug innovation and improving patient outcomes.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.

At Outpost, they are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company's lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Kadmon is a biopharmaceutical company focused on discovering, developing, and commercializing small molecules and biologics for the treatment of inflammatory and fibrotic diseases, as well as various cancers. Its key product candidates include KD025, an oral inhibitor targeting rho-associated coiled-coil kinase 2, currently undergoing Phase II clinical trials for chronic graft-versus-host disease and fibrotic conditions. Other candidates include KD045, aimed at fibrotic diseases, and KD033, an anti-PD-L1/IL-15 fusion protein for cancer treatment. Additionally, Kadmon is developing Tesevatinib for autosomal dominant polycystic kidney disease and CLOVIQUE for Wilson's disease. The company also offers ribavirin products for hepatitis treatment and provides patient support services. Founded in 2010 and headquartered in New York, Kadmon has established collaborations and license agreements with other firms to enhance its research and development efforts.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.

Amyris, Inc. is a biotechnology company based in Emeryville, California, founded in 2003. The company specializes in developing technology that creates microbial strains for the production of various high-value ingredients derived from renewable plant-sourced sugars. Its innovative platform enables the engineering of microbes to convert these sugars into products for the clean health and beauty, flavor and fragrance, and industrial markets, including cosmetics, solvents, lubricants, and fuels. Amyris operates under several brands, such as Biossance and Purecane, and is involved in biopharmaceutical drug discovery and production. Additionally, the company collaborates with the Infectious Disease Research Institute to advance vaccine development, including efforts related to COVID-19. Revenue is generated through the sale of renewable products, licensing of intellectual property, and collaborative research and development services.

Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.

VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Platelet BioGenesis is a biotechnology company focused on producing donor-independent human platelets from pluripotent stem cells for clinical use. Founded in 2014 and based in Cambridge, Massachusetts, the company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. Platelet BioGenesis distributes these bioreactor-produced platelets to hospitals and blood banks, aiming to provide a reliable source of platelets for patients worldwide. By specializing in the fields of platelets and drug discovery, the company is addressing critical needs in the medical community related to blood supply and treatment options.

Aadi Bioscience, Inc. is a clinical stage biopharmaceutical company based in Pacific Palisades, California, founded by Dr. Neil Desai in 2011. The company focuses on the development of a potentially best-in-class mTOR inhibitor, specifically ABI-009, aimed at treating patients with oncology, cardiovascular, and metabolic diseases. Aadi Bioscience is dedicated to addressing unmet medical needs through its innovative therapeutic approaches in these areas.

Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.

Bristol-Myers Squibb is a global biopharmaceutical company that focuses on the discovery, development, manufacturing, and marketing of innovative medicines for serious diseases. The company offers a range of products primarily in hematology, oncology, cardiovascular, and immunology therapeutic areas. Notable products include Opdivo, Eliquis, and Orencia, among others, which cater to various medical conditions such as cancer, stroke prevention, and rheumatoid arthritis. Bristol-Myers Squibb operates through collaborations with several partners, including Pfizer and AstraZeneca, enhancing its research and development capabilities. Founded in 1887 and headquartered in New York, the company has established a strong presence in the U.S. market, generating a significant portion of its revenue from American sales. Through its commitment to addressing critical health needs, Bristol-Myers Squibb continues to advance the field of biopharmaceuticals and improve patient outcomes.

Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.

Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, with a focus on developing innovative antibody-drug conjugate therapies for late-stage multiple myeloma and prostate cancer. The company was established based on technology exclusively licensed from the University of California, San Francisco, and developed in the laboratory of Dr. Bin Liu. Fortis Therapeutics aims to enhance treatment options for patients suffering from advanced adenocarcinoma and neuroendocrine cancer, leveraging its proprietary platform to create targeted therapies that improve clinical outcomes in late-stage cancer treatment.

Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.

Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.

At Outpost, they are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company's lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.

Akari Therapeutics is a clinical-stage biopharmaceutical company based in London, focused on developing and commercializing innovative treatments for rare and orphan autoimmune and inflammatory diseases. The company's lead product candidate, Coversin, is a second-generation complement inhibitor currently undergoing Phase II clinical trials for conditions such as paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics aims to provide life-transforming therapies that target specific pathways, including the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. Founded in 2015, the company is dedicated to addressing unmet medical needs in the field of autoimmune and inflammatory diseases.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative dermatologic and immunologic therapies. Founded by the team behind Vicept Therapeutics, Aclaris is dedicated to addressing significant unmet medical needs in dermatology and immunology, particularly in areas lacking FDA-approved treatments. The company operates in two main segments: therapeutics and contract research. The therapeutics segment focuses on creating novel drug candidates for immuno-inflammatory diseases, while the contract research segment generates revenue by providing laboratory services. Aclaris's pipeline includes drug candidates such as Zunsemetinib, an oral MK2 inhibitor, aiming to fill critical treatment gaps in the healthcare landscape.

Nabriva Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious bacterial infections. The company's lead product, lefamulin, is a semi-synthetic pleuromutilin antibiotic designed to treat community-acquired bacterial pneumonia and acute bacterial skin infections. It is currently undergoing clinical trials for additional applications, including pediatric infections, sexually transmitted infections, osteomyelitis, and prosthetic joint infections. Nabriva is also advancing CONTEPO, an epoxide antibiotic aimed at treating complicated urinary tract infections, and it is in clinical trials for peri-operative prophylaxis. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics has evolved from its earlier identity as a research institute focused on antibiotic development.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative dermatologic and immunologic therapies. Founded by the team behind Vicept Therapeutics, Aclaris is dedicated to addressing significant unmet medical needs in dermatology and immunology, particularly in areas lacking FDA-approved treatments. The company operates in two main segments: therapeutics and contract research. The therapeutics segment focuses on creating novel drug candidates for immuno-inflammatory diseases, while the contract research segment generates revenue by providing laboratory services. Aclaris's pipeline includes drug candidates such as Zunsemetinib, an oral MK2 inhibitor, aiming to fill critical treatment gaps in the healthcare landscape.

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company based in Redwood City, California, that specializes in the development, manufacture, and marketing of biosimilar therapeutics. It primarily targets the oncology and inflammatory disease markets with its product offerings. The company's flagship product, UDENYCA, is a biosimilar to Neulasta, designed to stimulate the production of granulocytes to enhance the body’s infection-fighting capabilities. Coherus is also advancing several other biosimilar candidates, including those for Humira and Enbrel, which have completed Phase III clinical studies. Additionally, the company is working on biosimilars for other biologics, including ranibizumab and aflibercept, as well as a small-molecule drug for metabolic conditions. Coherus BioSciences was founded in 2010 and has established various license agreements to support its product development initiatives.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer, particularly in the fields of hematology and oncology. Its lead candidate, momelotinib, is a selective JAK1, JAK2, and ACVR1 inhibitor that has been evaluated in two Phase 3 trials for myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, currently undergoing two Phase 1/2 clinical trials to explore its potential as a monotherapy and in combination with other therapies. Additionally, Sierra is developing SRA141, a small molecule inhibitor of cell division cycle 7 kinase, which is in preclinical research stages. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology retains global commercialization rights for its product candidates and aims to achieve successful registration and commercialization of its innovative therapies targeting the DNA Damage Response network.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for acute and chronic liver diseases, addressing significant unmet medical needs. The company's lead product, OCR-002, is an ammonia scavenger available in both intravenous and oral formulations, specifically targeting hyperammonemia. Ocera recently completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. The company is planning to engage with the FDA to explore potential development pathways for its intravenous program later this year.

Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development of innovative non-opioid medications aimed at treating lumbar radicular pain. The company focuses on creating products that address the needs of pain management practitioners and their patients, particularly those suffering from back pain. By prioritizing clinical and commercial development, Semnur aims to enhance the efficacy and safety of pain management therapies, ultimately improving treatment outcomes for underserved patient populations.

Carbylan Therapeutics, founded in 2004 and headquartered in Palo Alto, California, is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing proprietary combination therapies. The company's primary focus is on addressing pain associated with osteoarthritis of the knee, utilizing innovative approaches that include polysaccharides, biopolymers, and related pharmaceutical products. Carbylan Therapeutics aims to deliver effective therapies to meet significant unmet clinical needs in large and growing markets.

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative dermatologic and immunologic therapies. Founded by the team behind Vicept Therapeutics, Aclaris is dedicated to addressing significant unmet medical needs in dermatology and immunology, particularly in areas lacking FDA-approved treatments. The company operates in two main segments: therapeutics and contract research. The therapeutics segment focuses on creating novel drug candidates for immuno-inflammatory diseases, while the contract research segment generates revenue by providing laboratory services. Aclaris's pipeline includes drug candidates such as Zunsemetinib, an oral MK2 inhibitor, aiming to fill critical treatment gaps in the healthcare landscape.

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens. The company’s internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

Eiger BioPharmaceuticals is a late-stage biopharmaceutical company based in Palo Alto, California, dedicated to developing targeted therapies for rare and ultra-rare diseases. The company’s lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently undergoing Phase 3 clinical trials for the treatment of hepatitis delta virus (HDV) infection. Eiger's pipeline also includes Lambda, which is in Phase 2 trials and targets type III interferon receptors for HDV, as well as Lonafarnib for progeria and progeroid laminopathies. Additionally, the company is developing Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia and is also in Phase 2 for congenital hyperinsulinism. Eiger's focus is on addressing high unmet medical needs in serious diseases where no approved therapies currently exist.

NextWave Pharmaceuticals is a Cupertino, California-based pharmaceutical company that specializes in the development and commercialization of innovative drug delivery technologies. The company primarily focuses on creating once-daily liquid medications for the treatment of attention deficit/hyperactivity disorder (ADHD). By leveraging its proprietary technology, NextWave aims to provide effective treatment options that enhance patient compliance and address disorders related to the central nervous system.

Vicept (Vicept Therapeutics, Inc.), based in Malvern, Pennsylvania, is a privately held specialty biopharmaceutical company founded in August, 2009 with a mission to develop the first effective topically applied-therapy directed toward the erythema (skin redness) of rosacea and other dermatologic disorders characterized by redness and or 'flushing' of the skin.

Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.